Telix Pharmaceuticals Ltd.’s glioblastoma theranostic, TLX-101, is showing promising overall survival in a phase II trial in recurrent high-grade glioma. The targeted radiation therapy, combined with external beam radiation therapy, demonstrated a median overall survival of 12.4 months from treatment initiation and 32.2 months from initial diagnosis. The results significantly outperform the 9.9-month median survival typically observed with radiation therapy alone in recurrent glioblastoma patients.
Korea University Research & Business Foundation Sejong Campus has described thiobenzimidazole derivatives reported to be useful for the treatment of breast cancer.
China’s National Medical Products Administration (NMPA) has accepted Innocare Pharma Ltd.’s NDA for its second-generation pan-tropomyosin receptor kinase inhibitor, zurletrectinib (ICP-723), for treating adults and adolescents with advanced solid tumors harboring neurotrophic tyrosine receptor kinase gene fusions.
Radnet Inc. expanded its commitment to the use of AI in improving diagnosis of breast cancer with an all-stock purchase of Icad Inc. for approximately $103 million. The transaction is expected to close in the second or third quarter of 2025.
Antibody-drug conjugate developer Duality Biotherapeutics Inc. debuted on the Hong Kong Stock Exchange (HKEX) with a HK$1.64 billion (US$211.4 million) IPO April 15, making it one of the biggest offerings made under the HKEX’s Chapter 18A listing regime since 2020.
Momentum Therapeutics Inc. has described receptor-interacting serine/threonine-protein kinase 3 (RIPK3) inhibitors reported to be useful for the treatment of systematic inflammatory response syndrome, autoimmune disease, cancer, metabolic diseases, neurodegeneration and pain.
Researchers at Provincial Health Services Authority and University of British Columbia have synthesized radiolabeled peptides targeting gastrin-releasing peptide receptor (GRPR) reported to be useful for the diagnosis and treatment of cancer.
Samjin Pharmaceutical Co. Ltd. has disclosed stimulator of interferon genes protein (STING; TMEM173) agonists reported to be useful for the treatment of cancer, allergy, autoimmune diseases and inflammatory disorders.
A new study published in Nature Cancer reveals a novel regulatory mechanism of ferroptosis resistance that may help overcome therapeutic barriers in cancer treatment.
RSS
